-
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
24 Oct 2025 06:00 GMT
PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with …
-
Key 'lingering' symptoms to watch for this winter as doctor warns they could point to head and neck cancer
23 Oct 2025 12:20 GMT
… have a raspy voice, or your throat remains sore beyond … shift and any lumps or swellings in your throat … that patients with advanced head and neck cancers will be fast-tracked … people across the UK receive head and neck cancer diagnoses annually | GETTYThe …
-
<![CDATA[Buparlisib Plus Chemo Fails to Improve Head and Neck Cancer Survival]]>
21 Oct 2025 22:55 GMT
Among patients with PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), treatment with buparlisib and paclitaxel was not associated with an improvement in overall survival (OS) compared with paclitaxel alone, …
-
<![CDATA[Amivantamab Shows 45% Response Rate in Pretreated Head and Neck Cancer: OrigAMI-4 Findings]]>
21 Oct 2025 05:45 GMT
… in patients with recurrent or metastatic head and neck cancer who had received … least 2 tumor assessments or had stopped treatment for … Previously, single-agent chemotherapy or investigator’s choice therapies— … in the single digits or low teens, usually between …
-
International experts join conference in Hà Nội to address head and neck cancer challenges
20 Oct 2025 12:23 GMT
… the first session, themed 'Head and Neck Cancer', international experts discussed the … appropriate reconstruction flaps for partial or total maxillectomy, helping patients regain … of Facial Nerve Injury: Static or Dynamic Reconstruction' by Dr …
-
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
19 Oct 2025 15:29 GMT
… ;Patients with recurrent or metastatic head and neck cancer face an aggressive disease … of human papillomavirus–associated head and neck cancers: A population-based study … . Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and …
-
A Lump in the Neck or a Sore Throat That Won’t Go Away? It Could Be More Serious Than You Think
22 Oct 2025 23:37 GMT
… cost to you.
What Are Head and Neck Cancers?
Head and neck cancers are not just one disease … causes cancer. But in general, head and neck cancers begin when healthy cells in … throat, mouth sore or other signs of head and neck cancer, I am here to …
-
European biotech back on stage
24 Oct 2025 12:36 GMT
… willing to acquire late-stage or commercial assets to offset looming … III trial in locally advanced head and neck cancer. Interim data in 1H 2026 …
-
Dear Doctor: Can bunions on my foot eventually cause knee or hip pain?
21 Oct 2025 15:27 GMT
… at reducing the risk of head and neck cancer, it is critical that we … to ToYourGoodHealth@med.cornell.edu or send mail to 628 Virginia …
If you purchase a product or register for an account through … be collected, recorded, and/or stored by us and social …
-
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
19 Oct 2025 17:05 GMT
… decreases. Grade 3 or higher immune-related adverse … Studies Evaluating Pembrolizumab or Tislelizumab Plus Chemotherapy … receive either pembrolizumab or placebo plus carboplatin … cell lung cancer, and head and neck cancer. Ivonescimab is an investigational …
About
© 1995-2025